Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vertex Pharmaceuticals (NQ: VRTX ) 498.39 +6.13 (+1.25%) Streaming Delayed Price Updated: 2:02 PM EDT, Jul 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Vertex Pharmaceuticals < Previous 1 2 3 4 5 6 Next > 2 low-priced gene therapy stocks to speculate on January 08, 2024 Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe Via MarketBeat Exposures Product Safety Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings January 07, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Will the Biotech sector sustain its momentum in 2024? January 04, 2024 The iShares Biotechnology ETF (NASDAQ: IBB) emerged as a standout star, closing the first day of the year with a solid upswing of nearly 4%. Via MarketBeat Topics ETFs Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Climbs to New 52-Week High January 03, 2024 Via Investor Brand Network Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) is a Leading Gainer in 12/13 Morning Trading December 13, 2023 Via Investor Brand Network 2 gene-editing stocks reshaping hereditary disease treatments January 02, 2024 Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal Via MarketBeat CRISPR Therapeutics sets sights on gene-editing cures for disease December 27, 2023 On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for Via MarketBeat Exposures Product Safety Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8 December 18, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia December 15, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy December 13, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition December 11, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease December 08, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Appoints Nancy Thornberry to its Board of Directors December 05, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5 November 23, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire InvestorNewsBreaks – Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Featured in Barron’s Article for Potential Near ‘Breakthrough’ November 16, 2023 Via Investor Brand Network Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia November 16, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire MarketBeat Week in Review – 11/6 - 11/10 November 11, 2023 Stocks closed the week with a strong rally, but the rally may reverse when investors get the latest information about inflation and retail stocks next week Via MarketBeat Topics Artificial Intelligence Economy Exposures Artificial Intelligence Interest Rates Why you can make Vertex Pharmaceuticals a buy on any pullback November 08, 2023 Vertex stock is off its all-time highs after a slight miss on revenue, but the company's robust pipeline gives investors a reason to watch VRTX stock closely Via MarketBeat Exposures COVID-19 Vertex Reports Third Quarter 2023 Financial Results November 06, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex to Present New Data on Exagamglogene Autotemcel (exa-cel) at the American Society of Hematology (ASH) Annual Meeting and Exposition November 02, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA® at the North American Cystic Fibrosis Conference November 02, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex to Present at Upcoming Investor Conferences October 26, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Sets New 52-Week High in Tuesday Session October 17, 2023 Via Investor Brand Network Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Sets New 52-Week High in Friday Session October 13, 2023 Via Investor Brand Network Vertex to Announce Third Quarter 2023 Financial Results on November 6 October 10, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Appoints Michel Lagarde to its Board of Directors October 05, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting October 03, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5 September 15, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Researchers Awarded 2024 Breakthrough Prize in Life Sciences September 14, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference on September 13 August 30, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.